Journal Watch · Nature Communications · 2026

Loss of NCOA6 protein causes aggressive prostate cancer with EGFR overexpression and dependency.

These findings identify NCOA6 as a potent tumor suppressor and a clinically relevant biomarker to stratify PCa patients most likely to benefit from EGFR-targeted therapy.

Liu Y, Tong Z, Mo Q et al.Nature Communications3 min readPharma relevance 95/100

DOI: 10.1038/s41467-026-77701-yPMID: 42875450Study type: preclinical (animal / model) study

TL;DR

These findings identify NCOA6 as a potent tumor suppressor and a clinically relevant biomarker to stratify PCa patients most likely to benefit from EGFR-targeted therapy.

Key findings

  • Mechanistically, NCOA6 forms a repressive complex with nuclear transcription factor Y (NFY) at a distal EGFR enhancer, blocking p300 recruitment and limiting EGFR transcription.
  • Loss of NCOA6 derepresses EGFR, causing EGFR overexpression and rendering both androgen-sensitive and castration-resistant PCa highly dependent on EGFR signaling and exquisitely sensitive to EGFR inhibition.
  • These findings identify NCOA6 as a potent tumor suppressor and a clinically relevant biomarker to stratify PCa patients most likely to benefit from EGFR-targeted therapy.

What they did

Here, analysis of 1,719 human PCa specimens reveals frequent downregulation of the nuclear receptor coactivator 6 (NCOA6), particularly in metastatic disease. Genetic loss of NCOA6 accelerates tumor growth in human PCa xenografts, induces prostate tumorigenesis in mice, and cooperates with Pten haploinsufficiency to drive aggressive metastatic PCa.

Full abstract (original)

Background: Loss of tumor suppressors can drive carcinogenesis while simultaneously creating actionable therapeutic vulnerabilities. Epidermal growth factor receptor (EGFR) is frequently overexpressed in prostate cancer (PCa), yet EGFR inhibitors have shown limited clinical benefit, and the basis for this variability remains unclear.

What they did: Here, analysis of 1,719 human PCa specimens reveals frequent downregulation of the nuclear receptor coactivator 6 (NCOA6), particularly in metastatic disease. Genetic loss of NCOA6 accelerates tumor growth in human PCa xenografts, induces prostate tumorigenesis in mice, and cooperates with Pten haploinsufficiency to drive aggressive metastatic PCa.

Results & conclusions: Mechanistically, NCOA6 forms a repressive complex with nuclear transcription factor Y (NFY) at a distal EGFR enhancer, blocking p300 recruitment and limiting EGFR transcription. Loss of NCOA6 derepresses EGFR, causing EGFR overexpression and rendering both androgen-sensitive and castration-resistant PCa highly dependent on EGFR signaling and exquisitely sensitive to EGFR inhibition. These findings identify NCOA6 as a potent tumor suppressor and a clinically relevant biomarker to stratify PCa patients most likely to benefit from EGFR-targeted therapy.

Abstract © the authors / Nature Communications (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41467-026-77701-y · PubMed 42875450.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Nature Communications study find?

These findings identify NCOA6 as a potent tumor suppressor and a clinically relevant biomarker to stratify PCa patients most likely to benefit from EGFR-targeted therapy.

What type of study is this?

It is a preclinical (animal / model) study, published in Nature Communications in 2026. Here, analysis of 1,719 human PCa specimens reveals frequent downregulation of the nuclear receptor coactivator 6 (NCOA6), particularly in metastatic disease.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41467-026-77701-y. PubMed ID: 42875450. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Liu Y, Tong Z, Mo Q et al.. Loss of NCOA6 protein causes aggressive prostate cancer with EGFR overexpression and dependency.. Nature Communications (2026). DOI: 10.1038/s41467-026-77701-y.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/loss-of-ncoa6-protein-causes-aggressive-prostate-cancer-with-egfr-overex-77701y/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides